Anzeige
Mehr »
Lynx Broker
Login
Dienstag, 22.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H7JK ISIN: AU000000TLX2 Ticker-Symbol: T3X 
Tradegate
21.10.19
08:27 Uhr
0,985 Euro
+0,025
+2,60 %
Branche
Biotechnologie
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
TELIX PHARMACEUTICALS LIMITED Chart 1 Jahr
5-Tage-Chart
TELIX PHARMACEUTICALS LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
0,960
0,985
21.10.

Aktuelle News zur TELIX PHARMACEUTICALS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.10.TELIX PHARMACEUTICALS LIMITED: Telix and GE data - 68Ga supply for prostate cancer imaging5
TELIX PHARMACEUTICALS Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten!
06.10.TELIX PHARMACEUTICALS LIMITED: David Cade appointed Chief Business Officer and Head of IR9
02.10.TELIX PHARMACEUTICALS LIMITED: Telix to Acquire European Production Facility7
17.09.TELIX PHARMACEUTICALS LIMITED: App 3Y - Change in interests following exercise of options8
17.09.TELIX PHARMACEUTICALS LIMITED: App 3B - issue of shares following exercise of options3
16.09.Telix Pharmaceuticals - Regulatory progress in Japan and the US174Telix Pharmaceuticals is making progress on all fronts and recently announced that it has reached an agreement with the Japanese Pharmaceutical and Medical Device Agency (PMDA) to perform a 40-patient...
► Artikel lesen
29.08.TELIX PHARMACEUTICALS LIMITED: Telix to Commence Renal Cancer Imaging Study in Japan7
27.08.TELIX PHARMACEUTICALS LIMITED: FDA Pre-NDA Meeting Outcomes - TLX591-CDx illumet4
23.08.TELIX PHARMACEUTICALS LIMITED: App 3B for issue of shares under SPP - correction at Q85
22.08.TELIX PHARMACEUTICALS LIMITED: Appendix 4D and Financial Report for half-year to 30 June 194
22.08.TELIX PHARMACEUTICALS LIMITED: Appendix 3B - issue of shares under Share Purchase Plan3
20.08.TELIX PHARMACEUTICALS LIMITED: First Australian Patient Dosed in ZIRCON Phase III Trial5
19.08.TELIX PHARMACEUTICALS LIMITED: Telix Pharmaceuticals announces results of successful SPP4
08.08.Telix Pharmaceuticals to begin phase two prostate cancer imaging study2
07.08.TELIX PHARMACEUTICALS LIMITED: ENHANCING Prostate Cancer Clinical Study - Investor Overview1
07.08.TELIX PHARMACEUTICALS LIMITED: Telix and GenesisCare Commence Prostate Cancer Study2
05.08.Telix Pharmaceuticals - Another buyout of related assets146The world of prostate imaging received a shake-up with the recent US$450m buyout offer for Blue Earth from Bracco. Blue Earth's revenue derives primarily from its prostate imaging agent, Axumin (US$140m...
► Artikel lesen
05.08.Telix Pharma teams up with DKFZ for prostate surgery3
05.08.Telix Pharmaceuticals Limited: Telix Pharmaceuticals and German Cancer Research Center (DKFZ) Enter into Collaboration and Option Agreement for Image-Guided Prostate Surgery103MELBOURNE, Australia and HEIDELBERG, Germany, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) ("Telix", the "Company"), a clinical-stage biopharmaceutical company focused...
► Artikel lesen
04.08.TELIX PHARMACEUTICALS LIMITED: Collaboration with DKFZ for Image-Guided Prostate Surgery2
Seite:  Weiter >>
60 Nachrichten in den letzten 12 Monaten

Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1